Drugs / RGD Peptide
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT05653245 Comparator | Mar 2021 → Feb 2022 | periodontitis | Minia University | Completed | No outcome recorded |
| — | NCT06936605 Comparator | Apr → Sep 2025 overdue | periodontitis | Minia University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGD Peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06936605 ↗ |
| Modality | Peptide | “The arginyl-glycyl-aspartic acid (RGD) peptide is one of bioactive peptides” NCT05653245 ↗ |